PlainRecalls
FDA Drug Critical Class I Terminated

Meclizine Hydrochloride Tablets USP, 12.5 mg, packaged in a case of 24 bottles (100-count bottle), Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, 21801, NDC 59746-122-06

Reported: April 6, 2022 Initiated: March 8, 2022 #D-0767-2022

Product Description

Meclizine Hydrochloride Tablets USP, 12.5 mg, packaged in a case of 24 bottles (100-count bottle), Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, 21801, NDC 59746-122-06

Reason for Recall

Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles are Meclizine Hydrochloride

Details

Units Affected
12,174 bottles
Distribution
Product was distributed in Arkansas, Florida, North Carolina, South Carolina and Ohio.
Location
Salisbury, MD

Frequently Asked Questions

What product was recalled?
Meclizine Hydrochloride Tablets USP, 12.5 mg, packaged in a case of 24 bottles (100-count bottle), Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, 21801, NDC 59746-122-06. Recalled by Jubilant Cadista Pharmaceuticals, Inc.. Units affected: 12,174 bottles.
Why was this product recalled?
Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles are Meclizine Hydrochloride
Which agency issued this recall?
This recall was issued by the FDA Drug on April 6, 2022. Severity: Critical. Recall number: D-0767-2022.